170 related articles for article (PubMed ID: 15668815)
1. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
Lesinski GB; Valentino D; Hade EM; Jones S; Magro C; Chaudhury AR; Walker MJ; Carson WE
Cancer Immunol Immunother; 2005 Sep; 54(9):815-25. PubMed ID: 15668815
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
3. Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).
Chawla-Sarkar M; Leaman DW; Jacobs BS; Tuthill RJ; Chatterjee-Kishore M; Stark GR; Borden EC
J Interferon Cytokine Res; 2002 May; 22(5):603-13. PubMed ID: 12060499
[TBL] [Abstract][Full Text] [Related]
4. STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.
Machiraju D; Moll I; Gebhardt C; Sucker A; Buder-Bakhaya K; Schadendorf D; Hassel JC
Melanoma Res; 2018 Jun; 28(3):204-210. PubMed ID: 29485532
[TBL] [Abstract][Full Text] [Related]
5. Interferon alpha induction of Stat1 and Stat2 and their prognostic significance in carcinoid tumors.
Zhou Y; Wang S; Gobl A; Oberg K
Oncology; 2001; 60(4):330-8. PubMed ID: 11408801
[TBL] [Abstract][Full Text] [Related]
6. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.
Wong LH; Krauer KG; Hatzinisiriou I; Estcourt MJ; Hersey P; Tam ND; Edmondson S; Devenish RJ; Ralph SJ
J Biol Chem; 1997 Nov; 272(45):28779-85. PubMed ID: 9353349
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.
Radaeva S; Jaruga B; Kim WH; Heller T; Liang TJ; Gao B
Biochem J; 2004 Apr; 379(Pt 1):199-208. PubMed ID: 14690454
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma.
Carson WE
Clin Cancer Res; 1998 Sep; 4(9):2219-28. PubMed ID: 9748142
[TBL] [Abstract][Full Text] [Related]
9. The STAT2 activation process is a crucial target of Sendai virus C protein for the blockade of alpha interferon signaling.
Gotoh B; Takeuchi K; Komatsu T; Yokoo J
J Virol; 2003 Mar; 77(6):3360-70. PubMed ID: 12610111
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment.
Smith AP; Kirkwood JM; Edington HD; Jukic DM; Farkas DL; Becker D
Mol Imaging; 2003 Jan; 2(1):65-73. PubMed ID: 12926238
[TBL] [Abstract][Full Text] [Related]
11. The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line.
Badgwell B; Lesinski GB; Magro C; Abood G; Skaf A; Carson W
J Surg Res; 2004 Jan; 116(1):129-36. PubMed ID: 14732359
[TBL] [Abstract][Full Text] [Related]
12. Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha.
Li X; Leung S; Qureshi S; Darnell JE; Stark GR
J Biol Chem; 1996 Mar; 271(10):5790-4. PubMed ID: 8621447
[TBL] [Abstract][Full Text] [Related]
13. IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.
Zimmerer JM; Lehman AM; Ruppert AS; Noble CW; Olencki T; Walker MJ; Kendra K; Carson WE
Clin Cancer Res; 2008 Mar; 14(5):1438-45. PubMed ID: 18316567
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
15. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.
Kirkwood JM; Farkas DL; Chakraborty A; Dyer KF; Tweardy DJ; Abernethy JL; Edington HD; Donnelly SS; Becker D
Mol Med; 1999 Jan; 5(1):11-20. PubMed ID: 10072444
[TBL] [Abstract][Full Text] [Related]
16. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes.
Gimeno R; Lee CK; Schindler C; Levy DE
Mol Cell Biol; 2005 Jul; 25(13):5456-65. PubMed ID: 15964802
[TBL] [Abstract][Full Text] [Related]
17. Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells.
Clifford JL; Yang X; Walch E; Wang M; Lippman SM
Mol Cancer Ther; 2003 May; 2(5):453-9. PubMed ID: 12748307
[TBL] [Abstract][Full Text] [Related]
18. Selective STAT protein degradation induced by paramyxoviruses requires both STAT1 and STAT2 but is independent of alpha/beta interferon signal transduction.
Parisien JP; Lau JF; Rodriguez JJ; Ulane CM; Horvath CM
J Virol; 2002 May; 76(9):4190-8. PubMed ID: 11932384
[TBL] [Abstract][Full Text] [Related]
19. Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling.
Li X; Leung S; Kerr IM; Stark GR
Mol Cell Biol; 1997 Apr; 17(4):2048-56. PubMed ID: 9121453
[TBL] [Abstract][Full Text] [Related]
20. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
